Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInfectious Agent Antigen DetectionCPT cpt-87428-sars-cov-2-and-influenza-antigen-immunoassay
    Ask Trek AI about this page

    CPT 87428: SARS Coronavirus and Influenza Antigen Immunoassay

    Commercial payers pay $60 on average nationally for this procedure.

    CPT code 87428 describes a laboratory immunoassay performed to qualitatively or semiquantitatively detect and differentiate antigens from severe acute respiratory syndrome coronaviruses (including SARS–CoV–2) and influenza A and B from a patient respiratory specimen; service type: infectious agent antigen detection by immunoassay (qualitative/semiquantitative); typical site of service: clinical laboratory or hospital laboratory processing respiratory specimens for diagnostic evaluation of acute viral respiratory illness.

    For related coverage guidance, see recent payer policy updates: Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatment, HIV/AIDS Pharmacologic Prevention and Treatment, Long-Acting Injectable Antiretroviral Agents for HIV.

    Customize your policy alerts

    Sign up for cpt 87428 policy alerts

    Get alerted when payer policies referencing 87428 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial rates for CPT 87428 center around BUCA’s average commercial rate of $59.90, with individual payer medians and means varying notably. Blue Cross Blue Shield’s interquartile span is moderate at $20.70 (P75 $65.20 minus P25 $43.50), while Aetna shows a tighter middle spread of $14.00 (P75 $84.40 minus P25 $73.00). Cigna’s IQR is wide at $70.00 (P75 $81.60 minus P25 $11.80), and UnitedHealth Group has a sizable spread of $40.10 (P75 $73.50 minus P25 $34.40). BUCA’s commercial IQR is $27.60 (P75 $71.50 minus P25 $41.90).

    Dispersion indicates variability in negotiated rates: Aetna displays the tightest middle distribution, suggesting more consistency around its central values, while Cigna has the widest interquartile range, reflecting greater variability across contracts. UnitedHealth Group and BUCA sit between these extremes, and Blue Cross Blue Shield shows moderate dispersion.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 45-year-old patient with a history of selective IgA deficiency (D80.2) presents to an outpatient family medicine clinic in late fall with acute onset fever, cough, sore throat, and nasal congestion. The clinician performs a focused respiratory exam, documents symptoms and exposure history, and orders a multiplex immunoassay to distinguish among common viral causes of respiratory illness. A nasal or nasopharyngeal swab is collected by nursing staff and sent to the on-site clinical medical laboratory. The lab analyst performs CPT 87428 (immunoassay for SARS coronavirus antigens and influenza A/B) to provide qualitative/semiquantitative results. Results are routed back to the ordering family medicine physician (207Q00000X) via the electronic health record for clinical decision-making, including isolation, antiviral consideration, or further molecular testing such as CPT 87635 if warranted. Typical sites of service include outpatient clinics, urgent care centers, emergency departments, and hospital laboratories. The typical workflow: patient assessment → specimen collection → specimen accessioning → immunoassay testing (CPT 87428) → result verification and reporting → clinician review and follow-up actions.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    95Modifier 95 indicates that a service was provided via synchronous, real‑time audio‑video telehealth rather than in‑person. Per CMS, AAPC and professional associations, append modifier 95 to claim…- Use modifier 95 to indicate a service was furnished via synchronous, real‑time audiovisual telehealth (a live audio‑video conference between patient and provider) rather than in‑person. - Pair…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    291U00000X
    207Q00000X
    207R00000X
    261QM1000X
    246QH0000X
    1835P0200X
    2084F0202X
    175F00000X

    Related ICD-10-CM Codes

    14 rows

    ICD-10-CM CodeDescription
    B97.29Other coronavirus as the cause of diseases classified elsewhere
    D80.0Hereditary hypogammaglobulinemia
    D80.1Nonfamilial hypogammaglobulinemia
    D80.2Selective deficiency of immunoglobulin A [IgA]
    D80.3Selective deficiency of immunoglobulin G [IgG] subclasses
    D80.4Selective deficiency of immunoglobulin M [IgM]
    D80.5Immunodeficiency with increased immunoglobulin M [IgM]
    D80.6Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
    D80.8Other immunodeficiencies with predominantly antibody defects
    D81.0Severe combined immunodeficiency [SCID] with reticular dysgenesis

    Showing 1–10 of 14

    Related Payer Policy Updates

    Specialty: Infectious Disease1 / 3

    10 rows

    PolicyPayerEffective Date
    Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate) for HIV Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    HIV/AIDS Pharmacologic Prevention and Treatmentpremerabluecrossofwashington2026-10-01
    Long-Acting Injectable Antiretroviral Agents for HIVColorado Rocky Mountain Health Plans2026-10-01
    B-Hemolytic Streptococcus TestingOscar Health2026-10-01
    Human Immunodeficiency Virus (HIV) — Coverage Criteria for Testing and Resistance AssaysOscar Health2026-10-01
    Hepatitis Testing (A, B, C, D) Coverage CriteriaOscar Health2026-10-01
    Lyme Disease Testing Coverage CriteriaOscar Health2026-10-01
    Pathogen Panel TestingOscar Health2026-10-01
    Diagnostic Testing of Common Sexually Transmitted InfectionsOscar Health2026-10-01
    Testing for Vector-Borne InfectionsOscar Health2026-10-01

    Related Codes

    CPT-87260-ADENOVIRUS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87260: Adenovirus Antigen Detection by Immunofluorescence

    CPT-87265-BORDETELLA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87265: Bordetella Antigen Detection by Immunofluorescence

    CPT-87267-ENTEROVIRUS-DFA-ANTIGEN-DETECTION

    CPT 87267: Enterovirus Antigen Detection by DFA

    CPT-87269-GIARDIA-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87269: Giardia Antigen Detection by Immunofluorescence

    CPT-87270-CHLAMYDIA-TRACHOMATIS-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87270: Chlamydia trachomatis Antigen Detection by Immunofluorescence

    CPT-87271-CMV-DFA-ANTIGEN-DETECTION

    CPT 87271: CMV Antigen Detection by Direct Fluorescent Antibody

    CPT-87272-CRYPTOSPORIDIUM-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87272: Cryptosporidium Antigen Immunofluorescent Test

    CPT-87273-HSV-2-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87273: HSV-2 Antigen Detection by Immunofluorescence

    CPT-87274-HSV-1-ANTIGEN-IMMUNOFLUORESCENCE

    CPT 87274: HSV-1 Antigen Detection by Immunofluorescence

    CPT-87275-INFLUENZA-B-IMMUNOFLUORESCENT-ANTIGEN-DETECTION

    CPT 87275: Influenza B Antigen Detection by Immunofluorescence

    Showing 1–10 of 167

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    87635Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2Molecular PCR testing often used when higher sensitivity or confirmatory testing for SARS‑CoV‑2 is required after or instead of CPT 87428.
    87804Infectious agent antigen detection by immunoassay with direct optical observation; InfluenzaAlternative antigen immunoassay for influenza A/B; may be used instead of or in parallel with CPT 87428 depending on test platform.
    87811Infectious agent antigen detection by immunoassay with direct optical observation; SARS-CoV-2Alternate SARS‑CoV‑2 antigen assay CPT; may be used for point-of-care antigen testing while CPT 87428 covers multiplex platforms.
    87426Infectious agent antigen detection by immunoassay technique, qualitative or semiquantitative; SARS-CoV-2Closely related antigen immunoassay code for SARS‑CoV‑2; used for single-agent assays versus the multiplex coverage in CPT 87428.